112 related articles for article (PubMed ID: 31761713)
1. A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Carlo-Stella C; Delarue R; Scarfo L; Barde PJ; Nair A; Locatelli SL; Morello L; Magagnoli M; Vakkalanka S; Viswanadha S; Ferreri AJM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):78-86. PubMed ID: 31761713
[TBL] [Abstract][Full Text] [Related]
2. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A; Haverkos BM; Zain J; Radhakrishnan R; Lechowicz MJ; Devata S; Korman NJ; Pinter-Brown L; Oki Y; Barde PJ; Nair A; Routhu KV; Viswanadha S; Vakkalanka S; Iyer SP
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824175
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
4. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Flinn IW; O'Brien S; Kahl B; Patel M; Oki Y; Foss FF; Porcu P; Jones J; Burger JA; Jain N; Kelly VM; Allen K; Douglas M; Sweeney J; Kelly P; Horwitz S
Blood; 2018 Feb; 131(8):877-887. PubMed ID: 29191916
[TBL] [Abstract][Full Text] [Related]
5. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Flinn IW; Patel M; Oki Y; Horwitz S; Foss FF; Allen K; Douglas M; Stern H; Sweeney J; Kharidia J; Kelly P; Kelly VM; Kahl B
Am J Hematol; 2018 Nov; 93(11):1311-1317. PubMed ID: 30033575
[TBL] [Abstract][Full Text] [Related]
6. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
9. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
11. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
12. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.
Papadopoulos KP; Egile C; Ruiz-Soto R; Jiang J; Shi W; Bentzien F; Rasco D; Abrisqueta P; Vose JM; Tabernero J
Leuk Lymphoma; 2015 Jun; 56(6):1763-70. PubMed ID: 25300944
[TBL] [Abstract][Full Text] [Related]
15. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
[TBL] [Abstract][Full Text] [Related]
17. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
18. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
20. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.
Goto H; Izutsu K; Ennishi D; Mishima Y; Makita S; Kato K; Hanaya M; Hirano S; Narushima K; Teshima T; Nagai H; Ishizawa K
Int J Hematol; 2022 Dec; 116(6):911-921. PubMed ID: 36107394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
